These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
489 related items for PubMed ID: 17507609
21. Medical-economical aspects of high sensitivity C-reactive protein assay for the prediction of coronary heart disease. An analysis in Germany and Italy. Ess SM, Szucs TD. Ital Heart J; 2001 Mar; 2(3):181-8. PubMed ID: 11305529 [Abstract] [Full Text] [Related]
22. Effect of Helicobacter pylori eradication on incidence of gastric cancer in human and animal models: underlying biochemical and molecular events. Kabir S. Helicobacter; 2009 Jun; 14(3):159-71. PubMed ID: 19702845 [Abstract] [Full Text] [Related]
23. Clinical and economic effects of population-based Helicobacter pylori screening to prevent gastric cancer. Fendrick AM, Chernew ME, Hirth RA, Bloom BS, Bandekar RR, Scheiman JM. Arch Intern Med; 1999 Jan 25; 159(2):142-8. PubMed ID: 9927096 [Abstract] [Full Text] [Related]
24. Surveillance colonoscopy is cost-effective for patients with adenomas who are at high risk of colorectal cancer. Saini SD, Schoenfeld P, Vijan S. Gastroenterology; 2010 Jun 25; 138(7):2292-9, 2299.e1. PubMed ID: 20226186 [Abstract] [Full Text] [Related]
25. Cost-effectiveness of a potential prophylactic Helicobacter pylori vaccine in the United States. Rupnow MF, Chang AH, Shachter RD, Owens DK, Parsonnet J. J Infect Dis; 2009 Oct 15; 200(8):1311-7. PubMed ID: 19751153 [Abstract] [Full Text] [Related]
26. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence. Hung HF, Chen TH. Vaccine; 2009 Nov 12; 27(48):6770-6. PubMed ID: 19735755 [Abstract] [Full Text] [Related]
27. Duplicate breath testing to confirm eradication of Helicobacter pylori: incremental benefit and cost in 419 patients. Vakil N, Zullo A, Ricci C, Hassan C, Vaira D. Aliment Pharmacol Ther; 2008 Dec 01; 28(11-12):1304-8. PubMed ID: 18774949 [Abstract] [Full Text] [Related]
35. Cost-effectiveness of population screening for Helicobacter pylori in preventing gastric cancer and peptic ulcer disease, using simulation. Roderick P, Davies R, Raftery J, Crabbe D, Pearce R, Patel P, Bhandari P. J Med Screen; 2003 Dec 01; 10(3):148-56. PubMed ID: 14561268 [Abstract] [Full Text] [Related]
36. Review article: Helicobacter pylori eradication for the prevention of gastric cancer. De Vries AC, Kuipers EJ. Aliment Pharmacol Ther; 2007 Dec 01; 26 Suppl 2():25-35. PubMed ID: 18081646 [Abstract] [Full Text] [Related]
37. Treatment of Helicobacter pylori and prevention of gastric cancer. Cheung TK, Wong BC. J Dig Dis; 2008 Feb 01; 9(1):8-13. PubMed ID: 18251788 [Abstract] [Full Text] [Related]
38. The cost-effectiveness of competing strategies for the prevention of recurrent peptic ulcer hemorrhage. Ofman J, Wallace J, Badamgarav E, Chiou CF, Henning J, Laine L. Am J Gastroenterol; 2002 Aug 01; 97(8):1941-50. PubMed ID: 12190158 [Abstract] [Full Text] [Related]
39. Aspirin chemoprevention in patients with increased risk for colorectal cancer: a cost-effectiveness analysis. DuPont AW, Arguedas MR, Wilcox CM. Aliment Pharmacol Ther; 2007 Aug 01; 26(3):431-41. PubMed ID: 17635378 [Abstract] [Full Text] [Related]
40. Helicobacter pylori and gastric cancer. Forman D. Scand J Gastroenterol Suppl; 1996 Aug 01; 215():48-51. PubMed ID: 8722382 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]